Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer

Current Cancer Drug Targets

Volumn 14, Issue 2, 2014, Pages 167-180

  Ren, Jiang ^a   Yu, Chuanjiang ^a   Wu, Shifei ^a   Peng, Feng ^a   Jiang, Qianqian ^a   Zhang, Xuechao ^a   Zhong, Guoxing ^a   Shi, Huashan ^a   Chen, Xiang ^a   Su, Xiaolan ^a   Luo, Xinmei ^a   Zhu, Wen ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cationic liposome; FUS1 hIL 12 eukaryotic coexpression; Gene therapy; HuPBL NOD SCID; Lung cancer; Molecular mechanism

Indexed keywords

CISPLATIN; CYTOKINE; FAS ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 15; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID VECTOR; PROTEIN P53; STAT1 PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; CATION; TUMOR SUPPRESSOR PROTEIN; TUSC2 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION SYSTEM; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KAPLAN MEIER METHOD; LUNG CANCER; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MOUSE; NICK END LABELING; NONHUMAN; TUMOR CELL; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DRUG SCREENING; GENE TRANSFER; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NONOBESE DIABETIC MOUSE; PATHOLOGY; PLASMID; PROCEDURES; SCID MOUSE; SECONDARY; TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CATIONS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INTERLEUKIN-12; LIPOSOMES; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; TIME FACTORS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896324875     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140113115651     Document Type: Article

References (49)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. Cacancer J. Clin. 2012, 62 (1), 10-29.
2. Gettinger, S.; Lynch, T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin. Chest. Med. 2011, 32 (4), 839-851.
3. Ramalingam, S. S.; Owonikoko, T. K.; Khuri, F. R. Lung cancer: new biological insights and recent therapeutic advances. Ca-cancer J. Clin. 2011, 61 (2), 91-112.
4. Vachani, A.; Moon, E.; Wakeam, E.; Albelda, S. M. Gene therapy for mesothelioma and lung cancer. Am. J. Respir. Cell Mol. Biol. 2010, 42 (4), 385-393.
5. Ji, L.; Roth, J. A. Tumor suppressor FUS1 signaling pathway. J. Thorac. Oncol. 2008, 3 (4), 327-330.
6. Prudkin, L.; Behrens, C.; Liu, D. D.; Zhou, X.; Ozburn, N. C.; Bekele, B. N.; Minna, J. D.; Moran, C.; Roth, J. A.; Ji, L. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin. Cancer. Res. 2008, 14 (1), 41-47.
7. Deng, W.; Wu, G.; Ueda, K.; Xu, K.; Roth, J.; Ji, L. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Cancer Gene Ther. 2007, 15 (1), 29-39.
8. Deng, W. G.; Kawashima, H.; Wu, G.; Jayachandran, G.; Xu, K.; Minna, J. D.; Roth, J. A.; Ji, L. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic proteaseactivating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res. 2007, 67 (2), 709-717.
9. Ivanova, A.; Ivanov, S.; Pascal, V.; Lumsden, J.; Ward, J.; Morris, N.; Tessarolo, L.; Anderson, S.; Lerman, M. Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1. J. Pathol. 2007, 211 (5), 591-601.
10. Ivanova, A. V.; Ivanov, S. V.; Prudkin, L.; Nonaka, D.; Liu, Z.; Tsao, A.; Wistuba, I.; Roth, J.; Pass, H. I. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol. Cancer. 2009, 8 (1), 91-107.
11. Uzhachenko, R.; Issaeva, N.; Boyd, K.; Ivanov, S. V.; Carbone, D. P.; Ivanova, A. V. Tumour suppressor Fus1 provides a molecular link between inflammatory response and mitochondrial homeostasis. J. Pathol. 2012, 227 (4), 456-469.
12. Iclozan, C.; Gabrilovich, D. I. Recent advances in immunotherapy of lung cancer. J. Lung Cancer 2012, 11 (1), 1-11.
13. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3 (2), 133-146.
14. Del Vecchio, M.; Bajetta, E.; Canova, S.; Lotze, M. T.; Wesa, A.; Parmiani, G.; Anichini, A. Interleukin-12: biological properties and clinical application. Clin. Cancer. Res. 2007, 13 (16), 4677-4685.
15. Kerkar, S. P.; Restifo, N. P. The power and pitfalls of IL-12. Blood 2012, 119 (18), 4096-4097.
16. Heinzerling, L.; Burg, G.; Dummer, R.; Maier, T.; Oberholzer, P. A.; Schultz, J.; Elzaouk, L.; Pavlovic, J.; Moelling, K. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum. Gene Ther. 2005, 16 (1), 35-48.
17. Anwer, K.; Barnes, M.; Fewell, J.; Lewis, D.; Alvarez, R. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther. 2009, 17 (3), 360-369.
18. Qu, Y.; Chen, L.; Lowe, D. B.; Storkus, W. J.; Taylor, J. L. Combined Tbet and IL12 gene therapy Elicits and recruits superior antitumor immunity in vivo. Mol. Ther. 2012, 20 (3), 644-651.
19. Nikitina, E. Y.; Desai, S. A.; Zhao, X.; Song, W.; Luo, A. Z.; Gangula, R. D.; Slawin, K. M.; Spencer, D. M., Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res. 2005, 65 (10), 4309-4319.
20. Shanker, M.; Jin, J.; Branch, C. D.; Miyamoto, S.; Grimm, E. A.; Roth, J. A.; Ramesh, R., Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J. Drug Deliv. 2011, 2011, 465845.
21. Yu C.; Xiao W.; Zhang D.; Ou W.; Feng Z.; Zhu W. Study on Characterization of the Complexes of FUS1/hIL-12 with Cationic Liposome. J. Biomed. Eng. 2010, 27 (4), 859-864.
22. Ou, W.; Ye, S.; Yang, W.; Wang, Y.; Ma, Q.; Yu, C.; Shi, H.; Yuan, Z.; Zhong, G.; Ren, J. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1. Cancer Gene Ther. 2012, 19 (7), 489-498.
23. Garcia, S.; Dadaglio, G.; Gougeon, M. L. Limits of the human-PBL-SCID mice model: severe restriction of the Vβ T-cell repertoire of engrafted human T cells. Blood 1997, 89 (1), 329-336.
24. Lu, Y.; Zhang, Z.; Liu, Q.; Liu, B.; Song, X.; Wang, M.; Zhao, X.; Zhao, Q. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model. Biol. Pharm. Bull. 2007, 30 (1), 150-156.
25. Weidner, N.; Semple, J. P.; Welch, W. R.; Folkman, J., Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New Eng. J. Med. 1991, 324 (1), 1-8.
26. Broderick, L.; Yokota, S. J.; Reineke, J.; Mathiowitz, E.; Stewart, C. C.; Barcos, M.; Kelleher Jr, R. J.; Bankert, R. B. Human CD4+effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-γ, and eradicate tumor cells. J. Immunol. 2005, 174 (2), 898-906.
27. Watkins, S. K.; Egilmez, N. K.; Suttles, J.; Stout, R. D. IL-12 rapidly alters the functional profile of tumor-associated and tumorinfiltrating macrophages in vitro and in vivo. J. Immunol. 2007, 178 (3), 1357-1362.
28. Cao, X.; Leonard, K.; Collins, L. I.; Cai, S. F.; Mayer, J. C.; Payton, J. E.; Walter, M. J.; Piwnica-Worms, D.; Schreiber, R. D.; Ley, T. J. Interleukin 12 stimulates IFN-γ-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res. 2009, 69 (22), 8700-8709.
29. Hess, S. D.; Egilmez, N. K.; Bailey, N.; Anderson, T. M.; Mathiowitz, E.; Bernstein, S. H.; Bankert, R. B. Human CD4+T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J. Immunol. 2003, 170 (1), 400-412.
30. Watkins, S. K.; Li, B.; Richardson, K. S.; Head, K.; Egilmez, N. K.; Zeng, Q.; Suttles, J.; Stout, R. D. Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression. Eur. J. Immunol. 2009, 39 (8), 2126-2135.
31. Sato, N.; Patel, H. J.; Waldmann, T. A.; Tagaya, Y. The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc. Natl. Acad. Sci. 2007, 104 (2), 588-593.
32. Burkett, P. R.; Koka, R.; Chien, M.; Chai, S.; Boone, D. L.; Ma, A. Coordinate expression and trans presentation of interleukin (IL)-15Rα and IL-15 supports natural killer cell and memory CD8+T cell homeostasis. J. Exp. Med. 2004, 200 (7), 825-834.
33. Swann, J. B.; Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117 (5), 1137-1146.
34. Gri, G.; Chiodoni, C.; Gallo, E.; Stoppacciaro, A.; Liew, F. Y.; Colombo, M. P. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-γ A role for intrinsic tumor immunogenicity and IL-15. Cancer Res. 2002, 62 (15), 4390-4397.
35. Kilinc, M. O.; Aulakh, K. S.; Nair, R. E.; Jones, S. A.; Alard, P.; Kosiewicz, M. M.; Egilmez, N. K., Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+T effectors. J. Immunol. 2006, 177 (10), 6962-6973.
36. Wong, R. Apoptosis in cancer: from pathogenesis to treatment. J. Exp. Clin. Cancer Res. 2011, 30 (1), 87.
37. Lin, J.; Sun, T.; Ji, L.; Deng, W.; Roth, J.; Minna, J.; Arlinghaus, R. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 2007, 26 (49), 6989-6996.
38. Jaime-Ramirez, A. C.; Mundy-Bosse, B. L.; Kondadasula, S.; Jones, N. B.; Roda, J. M.; Mani, A.; Parihar, R.; Karpa, V.; Papenfuss, T. L.; LaPerle, K. M. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J. Immunol. 2011, 186 (6), 3401-3409.
39. Zhu, S.; Waguespack, M.; Barker, S. A.; Li, S. Doxorubicin directs the accumulation of interleukin-12-induced IFNγ into tumors for enhancing STAT1-dependent antitumor effect. Clin. Cancer Res. 2007, 13 (14), 4252-4260.
40. Kim, H. S.; Lee, M. S. STAT1 as a key modulator of cell death. Cell Signal. 2007, 19 (3), 454-465.
41. Townsend, P. A.; Scarabelli, T. M.; Davidson, S. M.; Knight, R. A.; Latchman, D. S.; Stephanou, A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J. Biol. Chem. 2004, 279 (7), 5811-5820.
42. Folkman, J. Angiogenesis: initiation and control. Ann. N. Y. Acad. Sci. 2006, 401 (1), 212-226.
43. Sitohy, B.; Nagy, J. A.; Dvorak, H. F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012, 72 (8), 1909-1914.
44. Lee, D. Y.; Deng, Z.; Wang, C.-H.; Yang, B. B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl. Acad. Sci. 2007, 104 (51), 20350-20355.
45. Gerber, S.; Moran, J.; Frelinger, J.; Frelinger, J.; Fenton, B.; Lord, E. Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Brit. J. Cancer. 2003, 88 (9), 1453-1461.
46. Sorensen, E. W.; Gerber, S. A.; Frelinger, J. G.; Lord, E. M. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-γ-dependent mechanisms. J. Immunol. 2010, 184 (4), 1858-1866.
47. Airoldi, I.; Di Carlo, E.; Cocco, C.; Caci, E.; Cilli, M.; Sorrentino, C.; Sozzi, G.; Ferrini, S.; Rosini, S.; Bertolini, G. IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PloS one 2009, 4 (7), e6119.
48. Tsai, Y. S.; Shiau, A. L.; Chen, Y.; Tsai, H. T.; Lee, H. L.; Tzai, T. S.; Wu, C. L. Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model. Vaccine 2009, 27 (39), 5383-5392.
49. Sgadari, C.; Angiolillo, A.; Tosato, G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996, 87 (9), 3877-3882.